Eagle Wealth Strategies LLC Takes $449,000 Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Eagle Wealth Strategies LLC bought a new stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 24,918 shares of the company’s stock, valued at approximately $449,000.

Several other institutional investors and hedge funds also recently made changes to their positions in TEVA. New Covenant Trust Company N.A. purchased a new stake in Teva Pharmaceutical Industries during the first quarter worth about $28,000. EntryPoint Capital LLC purchased a new position in shares of Teva Pharmaceutical Industries in the first quarter worth about $30,000. Beach Investment Counsel Inc. PA purchased a new position in shares of Teva Pharmaceutical Industries in the second quarter worth about $48,000. Byrne Asset Management LLC purchased a new position in shares of Teva Pharmaceutical Industries in the second quarter worth about $52,000. Finally, Industrial Alliance Investment Management Inc. bought a new position in shares of Teva Pharmaceutical Industries in the first quarter valued at approximately $54,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Wall Street Analysts Forecast Growth

TEVA has been the topic of several analyst reports. UBS Group lifted their target price on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. StockNews.com cut shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Thursday, October 3rd. Argus upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a report on Wednesday, July 10th. Barclays boosted their target price on shares of Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the company an “overweight” rating in a report on Thursday, August 1st. Finally, Jefferies Financial Group raised their price target on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the company a “buy” rating in a report on Thursday, June 27th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $18.89.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, insider Eric A. Hughes sold 24,537 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $17.25, for a total transaction of $423,263.25. Following the completion of the transaction, the insider now directly owns 45,060 shares of the company’s stock, valued at $777,285. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.55% of the stock is owned by insiders.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA stock traded down $0.19 on Wednesday, reaching $17.34. The company’s stock had a trading volume of 533,217 shares, compared to its average volume of 9,603,058. The stock’s fifty day simple moving average is $17.87 and its 200-day simple moving average is $16.45. Teva Pharmaceutical Industries Limited has a 1 year low of $8.06 and a 1 year high of $19.08. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 2.52. The company has a market capitalization of $19.64 billion, a price-to-earnings ratio of -42.76, a price-to-earnings-growth ratio of 1.22 and a beta of 0.88.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, July 31st. The company reported $0.58 earnings per share for the quarter, beating analysts’ consensus estimates of $0.55 by $0.03. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. The firm had revenue of $4.16 billion during the quarter, compared to analyst estimates of $3.99 billion. Analysts forecast that Teva Pharmaceutical Industries Limited will post 2.33 earnings per share for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.